Effect of natalizumab on circulating CD4+ T-cells in multiple sclerosis.
In multiple sclerosis (MS), treatment with the monoclonal antibody natalizumab effectively reduces the formation of acute lesions in the central nervous system (CNS). Natalizumab binds the integrin very late antigen (VLA)-4, expressed on the surface of immune cells, and inhibits VLA-4 dependent tran...
Main Authors: | Lars Börnsen, Jeppe Romme Christensen, Rikke Ratzer, Annette Bang Oturai, Per Soelberg Sørensen, Helle Bach Søndergaard, Finn Sellebjerg |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2012-01-01
|
Series: | PLoS ONE |
Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/23226199/?tool=EBI |
Similar Items
-
Pregnancy-Induced Changes in microRNA Expression in Multiple Sclerosis
by: Helle Bach Søndergaard, et al.
Published: (2021-01-01) -
Systemic inflammation in progressive multiple sclerosis involves follicular T-helper, Th17- and activated B-cells and correlates with progression.
by: Jeppe Romme Christensen, et al.
Published: (2013-01-01) -
Correction: Systemic Inflammation in Progressive Multiple Sclerosis Involves Follicular T-Helper, Th17- and Activated B-Cells and Correlates with Progression.
by: Jeppe Romme Christensen, et al.
Published: (2013-01-01) -
Cellular sources of dysregulated cytokines in relapsing-remitting multiple sclerosis
by: Romme Christensen Jeppe, et al.
Published: (2012-09-01) -
Endogenous interferon-β-inducible gene expression and interferon-β-treatment are associated with reduced T cell responses to myelin basic protein in multiple sclerosis.
by: Lars Börnsen, et al.
Published: (2015-01-01)